BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced financial results for the second quarter of 2016. For the quarter and six months ended June 30, 2016, net loss was $18.1 million and $33.7 million, respectively, compared to a net loss of $7.4 million and $10.8 million for the comparable periods in 2015. As of June 30, 2016, Aimmune had $171.8 million in cash, cash equivalents and investments compared to $199.8 million at December 31, 2015.
